These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
182 related articles for article (PubMed ID: 27556837)
1. Vedolizumab in Inflammatory Bowel Disease Associated with Autoimmune Liver Disease Pre- and Postliver Transplantation: A Case Series. Lim TY; Pavlidis P; Gulati S; Pirani T; Samaan M; Chung-Faye G; Dubois P; Irving P; Heneghan M; Hayee B Inflamm Bowel Dis; 2016 Oct; 22(10):E39-40. PubMed ID: 27556837 [No Abstract] [Full Text] [Related]
2. Vedolizumab in patients with concurrent primary sclerosing cholangitis and inflammatory bowel disease does not improve liver biochemistry but is safe and effective for the bowel disease. Christensen B; Micic D; Gibson PR; Yarur A; Bellaguarda E; Corsello P; Gaetano JN; Kinnucan J; Rao VL; Reddy S; Singh S; Pekow J; Rubin DT Aliment Pharmacol Ther; 2018 Mar; 47(6):753-762. PubMed ID: 29377235 [TBL] [Abstract][Full Text] [Related]
3. Vedolizumab is safe and effective in moderate-to-severe inflammatory bowel disease following liver transplantation. Wright AP; Fontana RJ; Stidham RW Liver Transpl; 2017 Jul; 23(7):968-971. PubMed ID: 28296011 [No Abstract] [Full Text] [Related]
4. Efficacy and safety of vedolizumab as a treatment option for moderate to severe refractory ulcerative colitis in two patients after liver transplant due to primary sclerosing cholangitis. Olmedo Martín RV; Amo Trillo V; González Grande R; Jiménez Pérez M Rev Esp Enferm Dig; 2017 Sep; 109(9):659-662. PubMed ID: 28724302 [TBL] [Abstract][Full Text] [Related]
5. Letter: vedolizumab for the management of inflammatory bowel disease in patients after liver transplantation for primary sclerosing cholangitis. Hartery K; O'Reilly S; Houlihan D; Doherty G; Mulcahy H; Cullen G; Sheridan J Aliment Pharmacol Ther; 2017 Jan; 45(2):376-378. PubMed ID: 27933688 [No Abstract] [Full Text] [Related]
14. Liver transplantation and inflammatory bowel disease. Papatheodoridis GV; Hamilton M; Rolles K; Burroughs AK J Hepatol; 1998 Jun; 28(6):1070-6. PubMed ID: 9672186 [No Abstract] [Full Text] [Related]
15. Vedolizumab has no efficacy on articular manifestations in patients with spondyloarthritis associated with inflammatory bowel disease. Paccou J; Nachury M; Duchemin C; Desreumaux P; Flipo RM; Pariente B Joint Bone Spine; 2019 Oct; 86(5):654-656. PubMed ID: 30711690 [No Abstract] [Full Text] [Related]
16. Liver transplantation for primary sclerosing cholangitis: timing, outcome, impact of inflammatory bowel disease and recurrence of disease. Wiesner RH Best Pract Res Clin Gastroenterol; 2001 Aug; 15(4):667-80. PubMed ID: 11492975 [TBL] [Abstract][Full Text] [Related]
17. The challenges of liver transplantation in children with primary sclerosing cholangitis. Venkat VL; Ranganathan S; Sindhi R Expert Rev Gastroenterol Hepatol; 2015 Mar; 9(3):289-94. PubMed ID: 25592492 [TBL] [Abstract][Full Text] [Related]
18. Sclerosing Cholangitis in Children and Adolescents. Mieli-Vergani G; Vergani D Clin Liver Dis; 2016 Feb; 20(1):99-111. PubMed ID: 26593293 [TBL] [Abstract][Full Text] [Related]